" class="no-js "lang="en-US"> Matthew Stoudt - Medtech Alert
Wednesday, October 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Matthew Stoudt

Matthew Stoudt

About Matthew Stoudt

Related Story

News

 AppliedVR Awarded Contract with VHA Innovation Ecosystem

AppliedVR Awarded Contract with VHA Innovation Ecosystem, a division of the United States Department of Veterans Affairs

December 8 2022

AppliedVR, an immersive therapeutics (ITx) pioneer advancing a novel, virtual reality-based approach to medicine, has […]

News

 FDA Grants AppliedVR Approval for First Virtual Reality Therapeutic to Treat Chronic Low Back Pain | Pharmtech Focus

FDA Grants AppliedVR Approval for First Virtual Reality Therapeutic to Treat Chronic Low Back Pain

November 17 2021

AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced that the U.S. […]